Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1999-06-21
2000-12-12
McKelvey, Terry
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
435243, 4353201, 435325, 435410, 536 241, C12Q 168, C07H 2104, C12N 100, C12N 510, C12N 1563
Patent
active
061596965
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to a method for the screening of therapeutic agents for the prevention and/or treatment of osteoporosis. The present invention relates to the isolation and cloning of the promoter regions of the gene encoding the mammalian bone morphogenetic protein-4 and the use of said promoter regions for the construction of recombinant expression vectors. The present invention further relates to cells which comprise recombinant expression vectors in which said promoter regions are operably linked to a reporter gene. Furthermore, the present invention relates to a method for the identification of therapeutic agents for the prevention and/or treatment of osteoporosis.
BACKGROUND OF THE INVENTION
Osteoporosis is a bone disorder characterized by the loss of bone mass, which leads to fragility and porosity of the bone of man. As a result patients suffering from osteoporosis have an increased fracture risk of the bones. Especially in postmenopausal women osteoporosis is one of the major syndromes, resulting from the reduction of estrogen production by the ovaries. In general, the loss of bone in postmenopausal women is prevented or treated by estrogen replacement: when administered at low levels, the estrogens have a beneficial effect on the loss of bone. However disadvantages of the so called estrogen replacement therapy are the unwanted side effects of estrogens on the endometrium, i.e. the increased risk of breast carcinomas and endometrium stimulation and/or hyperplasia, resulting in the increased risk of endometrium carcinomas.
In the light of these serious side effects there is a strong need for an alternative treatment of osteoporosis, in which the use of estrogens is avoided. It is an object of the invention to provide for such alternative and safer routes for the prevention and/or treatment of osteoporosis.
The bone morphogenetic proteins (BMPs) are a group of proteins that can induce de novo cartilage and bone formation, and appear to be essential for skeletal development during mammalian embryogenesis (Wang, Trends Biotechnol. 11, 379, 1993). Due to their osteoinductive properties the BMPs can be of clinical interest. Recently, it has become evident that early in the process of fracture healing the concentration of bone morphogenetic protein-4 (BMP-4) increases dramatically (Nakase et al., J. Bone Miner. Res. 9, 651, 1994 and Bostrom et al., J. Orthopaed. Res. 13, 357, 1995). In vivo experiments show that upregulation of BMP-4 transcription indeed promotes bone healing in mammals (Fang et al., Proc. Natl. Acad. Sci. USA. 93, 5753, 1966). These observations suggest an important role of BMP-4 in bone remodeling and fracture repair.
Although the role of BMP-4 seems to be crucial during many stages of development, the regulatory mechanisms underlying the specific expression of the BMP-4 gene are unknown. BMP-4 transcripts are expressed in several specific tissues, shown by Northern blot analysis and in situ hybridization. Two human BMP-4 transcripts have been identified, which are completely identical in their coding region, but are different in their 5' non-coding regions. Previous investigations showed a cell line dependent expression of both transcripts. Interestingly, the presence of multiple transcripts suggested an important difference in BMP-4 gene regulation. Furthermore, the short half life of BMP-4 mRNA suggests that the gene is primarily regulated at transcriptional level (Rogers et al., Cell. Growth. Differ. 7, 115, 1996).
SUMMARY OF THE INVENTION
According to the present invention it was found that the regulation of BMP-4 results in an alternative therapeutic route for fracture repair and the prevention or treatment of osteoporosis. Since the local production of BMP-4 seems to be more efficient in inducing bone formation than exogenous delivery of recombinant protein, the treatment according to the present invention is based on the modulation of the tissue-specific, local expression of BMP-4 in the osteoblasts. It was suprisingly found that the e
REFERENCES:
Van den Wijngaaard, et al. "Genomic Organization of the Human Bone morphogenetic protein-4 gene: Molecular basis for multiple transcripts." Bioschemical and biophysical Research Communications. 219 (3) Feb. 27, 1996.
J. Feng et al., "The mouse bone morphogenetic protein-4 gene" Journal of Biological Chemistry vol. 2780, No. 47, Nov. 24, 2995 pp. 28364-28373.
T. Kurihara, et al., "Murine Bone morphogenetic promoters and exons for the 5'-untranslated region" Biochemical and Biophysical Research Communication, vol. 192, No. 3, 1993 pp. 1049-1056.
Davis V., et al. "Correlation between low levels of estrogen receptors and estrogen responsiveness in two rat osteoblast-like cell lines" Journal of bone and Mineral Research vol. 9, No. 7, Jul. 1994, pp. 983-991.
Dijkema Rein
van den Wijngaard Arthur
Akzo Nobel N.V.
Blackstone William M.
Gormley Mary E.
McKelvey Terry
LandOfFree
Isolated human BMP-4 promoter region does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated human BMP-4 promoter region, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated human BMP-4 promoter region will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-215415